FDC Reports Q2 Net Profit Of ₹49.1 Crore Up From ₹28.4 Crore YoY

Market snapshot: FDC Limited reported a strong operational recovery for Q2 FY27, with consolidated net profit surging to ₹49.1 cr from ₹28.4 cr in the year-ago period. Top-line revenue expanded 21% YoY to reach ₹572 cr, supported by demand rebound in domestic formulations.

Data Snapshot

• Consolidated Net Profit for Q2 FY27 stood at ₹49.1 cr compared to ₹28.4 cr in Q2 FY26.
• Revenue from operations reached ₹572 cr in Q2 FY27, registering a 21% growth from ₹473 cr in the prior-year quarter.
• Quarterly EBITDA grew to ₹64.2 cr from ₹33.8 cr, with EBITDA margin expanding to 11.24% from 7.15% YoY.

What's Changed

• Net profit increased by 72.9% YoY (derived: ₹49.1 cr vs ₹28.4 cr).
• Quarterly revenue grew 21% YoY (derived: ₹572 cr vs ₹473 cr).
• EBITDA margin widened by 409 basis points YoY (derived: 11.24% vs 7.15%).

Key Takeaways

• Domestic formulation sales led revenue recovery during the quarter.
• Operational leverage drove EBITDA higher to ₹64.2 cr.
• International formulations continue to provide secondary top-line momentum.

SAHI Perspective

FDC's Q2 performance demonstrates operating efficiency leverage returning to the core business. A key factor to track is whether domestic formulations demand can sustain this double-digit top-line trajectory into the second half of the fiscal year.

Market Implications

The significant margin relief provides earnings visibility for FDC after a challenging prior-year quarter. Consistent margin defense around the 11-12% mark will be critical for mid-cap pharma sector valuation support.

Trading Signals

Market Bias: Bullish

Strong top-line revenue expansion of 21% YoY to ₹572 cr alongside a 72.9% increase in net profit to ₹49.1 cr highlights solid earnings acceleration.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Sustained quarterly EBITDA margins above 11%
• Domestic formulation sales growth momentum
• Execution of share buyback program

Time Horizon: Near-term (0-3 months)

Industry Context

Indian pharmaceutical manufacturers have faced domestic growth fluctuations alongside raw material cost shifts. Operational recovery in branded domestic formulations provides structural stability to cash flows.

Key Risks to Watch

• Volatile raw material costs impacting operating margins
• Regulatory compliance delays for international exports

Recent Developments

FDC announced board approval for an equity share buyback program alongside its quarterly disclosures. Additionally, the company secured US FDA approval for Cefixime Oral Suspension earlier in the fiscal year.

Closing Insight

With revenue and profitability returning to growth, FDC's execution on domestic market volume will dictate sustainable valuation re-rating.

High Performance Trading with SAHI.